Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Fortrea Holdings Inc. (FTRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: FTRE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -27.34% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 724.31M USD | Price to earnings Ratio - | 1Y Target Price 12.05 |
Price to earnings Ratio - | 1Y Target Price 12.05 | ||
Volume (30-day avg) 2340438 | Beta - | 52 Weeks Range 8.00 - 40.63 | Updated Date 03/29/2025 |
52 Weeks Range 8.00 - 40.63 | Updated Date 03/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.03 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date 2025-03-10 | When Before Market | Estimate 0.3653 | Actual 0.18 |
Profitability
Profit Margin -12.18% | Operating Margin (TTM) -4.02% |
Management Effectiveness
Return on Assets (TTM) -1.77% | Return on Equity (TTM) -17.65% |
Valuation
Trailing PE - | Forward PE 29.41 | Enterprise Value 1804306000 | Price to Sales(TTM) 0.27 |
Enterprise Value 1804306000 | Price to Sales(TTM) 0.27 | ||
Enterprise Value to Revenue 0.67 | Enterprise Value to EBITDA 92.35 | Shares Outstanding 90200000 | Shares Floating 78282776 |
Shares Outstanding 90200000 | Shares Floating 78282776 | ||
Percent Insiders 0.3 | Percent Institutions 105.53 |
Analyst Ratings
Rating 3 | Target Price 22.84 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold 10 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Fortrea Holdings Inc.
Company Overview
History and Background
Fortrea Holdings Inc. was formed in 2023 following a spin-off from Labcorp. It focuses on providing clinical development and commercialization solutions to the biopharmaceutical industry.
Core Business Areas
- Clinical Development: Provides comprehensive clinical trial management services, from early-phase studies to late-stage trials, including study design, patient recruitment, data management, and regulatory submissions.
- Commercialization: Offers solutions to support the launch and commercial success of pharmaceutical products, including market access strategies, medical communications, and sales force effectiveness.
Leadership and Structure
Raymond F. Huml is the CEO. The company operates with a functional organizational structure, divided into clinical development and commercialization services.
Top Products and Market Share
Key Offerings
- Clinical Trial Management: Encompasses the planning, execution, and monitoring of clinical trials across various therapeutic areas. Market share is difficult to precisely ascertain, but Fortrea competes with major CROs (Contract Research Organizations). Competitors include IQVIA, Parexel, PPD (Thermo Fisher Scientific), and ICON plc. They generate significant revenue from large pharmaceutical company contracts.
- Commercialization Services: Provides post-approval services such as market access consulting, medical affairs support, and real-world evidence generation. Competitors include Syneos Health and several specialized consulting firms. This market is fragmented, making market share difficult to quantify.
Market Dynamics
Industry Overview
The CRO industry is experiencing growth driven by increasing R&D spending by pharmaceutical companies, the complexity of clinical trials, and the need for specialized expertise. The commercialization services market is also expanding due to the increasing importance of demonstrating product value and securing market access.
Positioning
Fortrea positions itself as a global CRO providing comprehensive clinical development and commercialization solutions. Its competitive advantage lies in its scale, expertise, and integrated service offerings.
Total Addressable Market (TAM)
The global CRO market is estimated at over $70 billion. Fortrea is positioned to capture a significant portion of this TAM through its comprehensive service offerings and global reach.
Upturn SWOT Analysis
Strengths
- Comprehensive service offerings
- Global reach
- Experienced management team
- Strong relationships with pharmaceutical companies
- Focus on clinical development and commercialization
Weaknesses
- Relatively new company post spin-off
- Integration challenges following the spin-off
- Dependence on pharmaceutical R&D spending
- Potential for client concentration
- Limited brand recognition compared to established CROs
Opportunities
- Growing demand for CRO services
- Expansion into new therapeutic areas
- Strategic acquisitions
- Increased outsourcing by pharmaceutical companies
- Adoption of new technologies
Threats
- Economic downturn affecting pharmaceutical R&D spending
- Increased competition from other CROs
- Regulatory changes
- Pricing pressure
- Data security breaches
Competitors and Market Share
Key Competitors
- IQVIA (IQV)
- Thermo Fisher Scientific (TMO)
- Syneos Health (SYNH)
- ICON plc (ICLR)
- Parexel (Not Publicly Traded)
Competitive Landscape
Fortrea operates in a highly competitive market. IQVIA and Thermo Fisher Scientific are the largest players with significant market share. Fortrea differentiates itself through its integrated service offerings and focus on clinical development and commercialization.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the recent spin-off.
Future Projections: Analyst projections estimate revenue growth in the mid-single digits as Fortrea capitalizes on the growing CRO market.
Recent Initiatives: Fortrea focuses on strengthening its clinical trial capabilities and expanding its commercialization service offerings. Strategic partnerships are key.
Summary
Fortrea is a relatively new CRO with a strong backing due to its split from Labcorp with focus on growth through its integrated clinical and commercial services. As it finds its place in a very competitive market, its growth will depend on winning contracts from pharmaceutical giants and maintaining a strategic advantage. Focus for Fortrea needs to be on capitalizing on outsourcing trends to further improve financials.
Similar Companies
- IQV
- TMO
- SYNH
- ICLR
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Market Research Reports
- Analyst Estimates
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fortrea Holdings Inc.
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2023-07-03 | CEO & Chairman Mr. Thomas H. Pike | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15500 | Website https://www.fortrea.com |
Full time employees 15500 | Website https://www.fortrea.com | ||
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical services that provides development and consulting services to clinical pharmacology and clinical development spectrum. The company also offers delivery models that include full service, functional service provider, and hybrid service structures. In addition, it delivers phase I " IV clinical trial management, clinical pharmacology, and consulting services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.